Skip to main content
. Author manuscript; available in PMC: 2015 Jul 14.
Published in final edited form as: Annu Rev Clin Psychol. 2009;5:249–275. doi: 10.1146/annurev.clinpsy.032408.153502

Figure 5.

Figure 5

Comparative deficits in visual activation in schizophrenia patients versus cats treated with the NMDA antagonist 2-amino-5-phosphonovaleric acid (APV). (a) ssVEP amplitude (signal-to-noise ratio) in schizophrenic patients in response to magnocellular-biased stimuli. (From Butler et al. 2005.) (b) Effects of APV infusion into cat lateral geniculate nucleus (LGN) in response to stimulation. (From Kwon et al. 1991.)